Enviar búsqueda
Cargar
Working in a_regulated_environment_presentation_ngan-winward
•
2 recomendaciones
•
5,568 vistas
B
bio-link
Seguir
Empresariales
Salud y medicina
Denunciar
Compartir
Denunciar
Compartir
1 de 74
Recomendados
Understanding FDA Regulations
Understanding FDA Regulations
Beth Friedland
Overview of FDA Drug Manufacturing Requirements
Overview of FDA Drug Manufacturing Requirements
Michael Swit
2009.10.15 quality assurance-for-medical-devices-in-china
2009.10.15 quality assurance-for-medical-devices-in-china
M.H.Keerthi Chandra
Labeling/Advertising and Promotion, Import/Export, and Enforcement Actions
Labeling/Advertising and Promotion, Import/Export, and Enforcement Actions
Michael Swit
Latest Developments in and the Future of the Regulatory Landscape for Approv...
Latest Developments in and the Future of the Regulatory Landscape for Approv...
Michael Swit
AzCI presents: Medical Device Regulations through the FDA
AzCI presents: Medical Device Regulations through the FDA
AnitaBell
COMBINATION PRODUCTS – Perspectives on FDA Regulation
COMBINATION PRODUCTS – Perspectives on FDA Regulation
Michael Swit
Combination Products
Combination Products
chemist874
Más contenido relacionado
La actualidad más candente
Naresh... anda ppt
Naresh... anda ppt
Malla Reddy College of Pharmacy
Application and Regulation of the Use of Photosynthetic Microorganisms in Bio...
Application and Regulation of the Use of Photosynthetic Microorganisms in Bio...
David Glass
Recent FDA Developments in Digital Health & Clinical Decision Support Software
Recent FDA Developments in Digital Health & Clinical Decision Support Software
Michael Swit
NDA and ANDA regulatory approval process
NDA and ANDA regulatory approval process
JagrutiKale1
David Glass Plenary Presentation at 4th Algal Biomass, Biofuels and Bioproduc...
David Glass Plenary Presentation at 4th Algal Biomass, Biofuels and Bioproduc...
David Glass
The Rough Waters of the Regulatory Environment
The Rough Waters of the Regulatory Environment
Jonathan Servoss
Premarket Notification The 510(k) Process
Premarket Notification The 510(k) Process
Michael Swit
Good Manufacturing Practice (GMP) 2day course
Good Manufacturing Practice (GMP) 2day course
Jo Havemann
Avoiding Pitfalls in the Regulatory Path - MaRS Best Practices
Avoiding Pitfalls in the Regulatory Path - MaRS Best Practices
MaRS Discovery District
Medical Device Regulation
Medical Device Regulation
Sam Nixon
"Scientific Exchange -- New Interpretations??"
"Scientific Exchange -- New Interpretations??"
Michael Swit
David Glass Regulatory Presentation and Case Study BIO Pac Rim Conference Dec...
David Glass Regulatory Presentation and Case Study BIO Pac Rim Conference Dec...
David Glass
Dr. Ravi Dhar reviews "IP Barriers in Generic Vaccines in 2014"
Dr. Ravi Dhar reviews "IP Barriers in Generic Vaccines in 2014"
Dr. Ravi Dhar
ANDA FDA APPLICATION
ANDA FDA APPLICATION
Roshan Bodhe
Jpm 2016-presentation-11416-final8 k
Jpm 2016-presentation-11416-final8 k
Exactir
Pharmaceutical Industry Terminology
Pharmaceutical Industry Terminology
Thomson Reuters
Generic Drugs and Biosimilars
Generic Drugs and Biosimilars
Michael Swit
Strategies for Developing & Commercializing Biobetters & Biosimilars
Strategies for Developing & Commercializing Biobetters & Biosimilars
ConferenceForum
Combination Products, Orphan Drugs and OTC Drugs
Combination Products, Orphan Drugs and OTC Drugs
Michael Swit
Prescription drug user fee act and its influence on review time and budget
Prescription drug user fee act and its influence on review time and budget
SriramNagarajan17
La actualidad más candente
(20)
Naresh... anda ppt
Naresh... anda ppt
Application and Regulation of the Use of Photosynthetic Microorganisms in Bio...
Application and Regulation of the Use of Photosynthetic Microorganisms in Bio...
Recent FDA Developments in Digital Health & Clinical Decision Support Software
Recent FDA Developments in Digital Health & Clinical Decision Support Software
NDA and ANDA regulatory approval process
NDA and ANDA regulatory approval process
David Glass Plenary Presentation at 4th Algal Biomass, Biofuels and Bioproduc...
David Glass Plenary Presentation at 4th Algal Biomass, Biofuels and Bioproduc...
The Rough Waters of the Regulatory Environment
The Rough Waters of the Regulatory Environment
Premarket Notification The 510(k) Process
Premarket Notification The 510(k) Process
Good Manufacturing Practice (GMP) 2day course
Good Manufacturing Practice (GMP) 2day course
Avoiding Pitfalls in the Regulatory Path - MaRS Best Practices
Avoiding Pitfalls in the Regulatory Path - MaRS Best Practices
Medical Device Regulation
Medical Device Regulation
"Scientific Exchange -- New Interpretations??"
"Scientific Exchange -- New Interpretations??"
David Glass Regulatory Presentation and Case Study BIO Pac Rim Conference Dec...
David Glass Regulatory Presentation and Case Study BIO Pac Rim Conference Dec...
Dr. Ravi Dhar reviews "IP Barriers in Generic Vaccines in 2014"
Dr. Ravi Dhar reviews "IP Barriers in Generic Vaccines in 2014"
ANDA FDA APPLICATION
ANDA FDA APPLICATION
Jpm 2016-presentation-11416-final8 k
Jpm 2016-presentation-11416-final8 k
Pharmaceutical Industry Terminology
Pharmaceutical Industry Terminology
Generic Drugs and Biosimilars
Generic Drugs and Biosimilars
Strategies for Developing & Commercializing Biobetters & Biosimilars
Strategies for Developing & Commercializing Biobetters & Biosimilars
Combination Products, Orphan Drugs and OTC Drugs
Combination Products, Orphan Drugs and OTC Drugs
Prescription drug user fee act and its influence on review time and budget
Prescription drug user fee act and its influence on review time and budget
Similar a Working in a_regulated_environment_presentation_ngan-winward
Usfda sana 1
Usfda sana 1
sanjay patil
USFDA GUIDLINES
USFDA GUIDLINES
Raj Tiwari
What is FDA?
What is FDA?
Pharmaguideline
Regulatory affair - Introduction
Regulatory affair - Introduction
Dr. Jigar Vyas
USFDA
USFDA
vivek vyas
Usfda swatee
Usfda swatee
Saket Singh
Usfda
Usfda
Medaramitla Sadhana reddy
Agencies dhwani
Agencies dhwani
Patel Parth
Roshan (1)
Roshan (1)
PranitaJirvankar
Ind (investigational new drug application) and nda
Ind (investigational new drug application) and nda
swati2084
Regulatory Compliance in Clinical Research: Navigating the FDA and Other Agen...
Regulatory Compliance in Clinical Research: Navigating the FDA and Other Agen...
ClinosolIndia
Usfda ppn
Usfda ppn
priyanka.p. Nayak
Ppt 1 overview of regulatory affairs and diff bodies_august2016_final
Ppt 1 overview of regulatory affairs and diff bodies_august2016_final
Rajashri Survase Ojha
GTPs vs. cGMPs
GTPs vs. cGMPs
wrtolbert
US FDA
US FDA
Suvarta Maru
Fda gmp compliance for the Life Science Industry
Fda gmp compliance for the Life Science Industry
dmanalan
FDA’s drug review process
FDA’s drug review process
Anthony Melvin Crasto Ph.D
Good Manufacturing Practice (GMP) | Arrelic Insights
Good Manufacturing Practice (GMP) | Arrelic Insights
Arrelic
INDA- Investigation New Drug Application
INDA- Investigation New Drug Application
Dr. Jigar Vyas
Food and Drugs Administration.pptx
Food and Drugs Administration.pptx
Ankitsharma811886
Similar a Working in a_regulated_environment_presentation_ngan-winward
(20)
Usfda sana 1
Usfda sana 1
USFDA GUIDLINES
USFDA GUIDLINES
What is FDA?
What is FDA?
Regulatory affair - Introduction
Regulatory affair - Introduction
USFDA
USFDA
Usfda swatee
Usfda swatee
Usfda
Usfda
Agencies dhwani
Agencies dhwani
Roshan (1)
Roshan (1)
Ind (investigational new drug application) and nda
Ind (investigational new drug application) and nda
Regulatory Compliance in Clinical Research: Navigating the FDA and Other Agen...
Regulatory Compliance in Clinical Research: Navigating the FDA and Other Agen...
Usfda ppn
Usfda ppn
Ppt 1 overview of regulatory affairs and diff bodies_august2016_final
Ppt 1 overview of regulatory affairs and diff bodies_august2016_final
GTPs vs. cGMPs
GTPs vs. cGMPs
US FDA
US FDA
Fda gmp compliance for the Life Science Industry
Fda gmp compliance for the Life Science Industry
FDA’s drug review process
FDA’s drug review process
Good Manufacturing Practice (GMP) | Arrelic Insights
Good Manufacturing Practice (GMP) | Arrelic Insights
INDA- Investigation New Drug Application
INDA- Investigation New Drug Application
Food and Drugs Administration.pptx
Food and Drugs Administration.pptx
Más de bio-link
Writing Effective NSF Proposals
Writing Effective NSF Proposals
bio-link
NSF and Community College programs TX 2017
NSF and Community College programs TX 2017
bio-link
Biomanufacturing 2016
Biomanufacturing 2016
bio-link
June2016 bio link_biotechisstem
June2016 bio link_biotechisstem
bio-link
Se3 d workshop presentation biolink
Se3 d workshop presentation biolink
bio-link
Single use technologies in biomanufacturing
Single use technologies in biomanufacturing
bio-link
2016 Biotechnician Assistant Credentialing Exam
2016 Biotechnician Assistant Credentialing Exam
bio-link
photosynthesis and cellular respiration
photosynthesis and cellular respiration
bio-link
Team based learning in biotechnology courses
Team based learning in biotechnology courses
bio-link
Bioscience Laboratory Workforce Skills - part II
Bioscience Laboratory Workforce Skills - part II
bio-link
Coalition of State Bioscience Institutes presentation 11 18_13
Coalition of State Bioscience Institutes presentation 11 18_13
bio-link
Bioscience Laboratory Workforce Skills - part I
Bioscience Laboratory Workforce Skills - part I
bio-link
Sbir phase iicc d brown - 2013 ate pi conference
Sbir phase iicc d brown - 2013 ate pi conference
bio-link
Ate presentation schrag_102413
Ate presentation schrag_102413
bio-link
Core Competencies for the Bioscience Laboratory
Core Competencies for the Bioscience Laboratory
bio-link
Stem Cell Technologies: New program development, sustainability, and dissemi...
Stem Cell Technologies: New program development, sustainability, and dissemi...
bio-link
Development of a Technical Program in Stem Cell Science
Development of a Technical Program in Stem Cell Science
bio-link
NSF support for Biotechnology Technician Education
NSF support for Biotechnology Technician Education
bio-link
Open session Summer Fellows Forum 2013
Open session Summer Fellows Forum 2013
bio-link
Molecular murder mysteries 2013
Molecular murder mysteries 2013
bio-link
Más de bio-link
(20)
Writing Effective NSF Proposals
Writing Effective NSF Proposals
NSF and Community College programs TX 2017
NSF and Community College programs TX 2017
Biomanufacturing 2016
Biomanufacturing 2016
June2016 bio link_biotechisstem
June2016 bio link_biotechisstem
Se3 d workshop presentation biolink
Se3 d workshop presentation biolink
Single use technologies in biomanufacturing
Single use technologies in biomanufacturing
2016 Biotechnician Assistant Credentialing Exam
2016 Biotechnician Assistant Credentialing Exam
photosynthesis and cellular respiration
photosynthesis and cellular respiration
Team based learning in biotechnology courses
Team based learning in biotechnology courses
Bioscience Laboratory Workforce Skills - part II
Bioscience Laboratory Workforce Skills - part II
Coalition of State Bioscience Institutes presentation 11 18_13
Coalition of State Bioscience Institutes presentation 11 18_13
Bioscience Laboratory Workforce Skills - part I
Bioscience Laboratory Workforce Skills - part I
Sbir phase iicc d brown - 2013 ate pi conference
Sbir phase iicc d brown - 2013 ate pi conference
Ate presentation schrag_102413
Ate presentation schrag_102413
Core Competencies for the Bioscience Laboratory
Core Competencies for the Bioscience Laboratory
Stem Cell Technologies: New program development, sustainability, and dissemi...
Stem Cell Technologies: New program development, sustainability, and dissemi...
Development of a Technical Program in Stem Cell Science
Development of a Technical Program in Stem Cell Science
NSF support for Biotechnology Technician Education
NSF support for Biotechnology Technician Education
Open session Summer Fellows Forum 2013
Open session Summer Fellows Forum 2013
Molecular murder mysteries 2013
Molecular murder mysteries 2013
Último
Ethical stalking by Mark Williams. UpliftLive 2024
Ethical stalking by Mark Williams. UpliftLive 2024
Winbusinessin
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
TalentView
Intellectual Property Licensing Examples
Intellectual Property Licensing Examples
amberjiles31
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
IMARC Group
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
Helene Heckrotte
NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023
Steve Rader
Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024
Borderless Access
Al Taj Al Malaki Company Profile -------
Al Taj Al Malaki Company Profile -------
ThanzirNazer
AL Satwa Dubai Call Girls +971552825767 Call Girls In AL Karama
AL Satwa Dubai Call Girls +971552825767 Call Girls In AL Karama
Dubai Escort Service +971564212067 Top Punjabi Model Call In Dubai
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BBPMedia1
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
lokeshwarmaha
The End of Business as Usual: Rewire the Way You Work to Succeed in the Consu...
The End of Business as Usual: Rewire the Way You Work to Succeed in the Consu...
Brian Solis
Data skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story points
yasinnathani
IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...
IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...
AustraliaChapterIIBA
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access
Q2 2024 APCO Geopolitical Radar - The Global Operating Environment for Business
Q2 2024 APCO Geopolitical Radar - The Global Operating Environment for Business
APCO
MoneyBridge Pitch Deck - Investor Presentation
MoneyBridge Pitch Deck - Investor Presentation
baron83
Company Profile and SWOT Analysis Product List.pdf
Company Profile and SWOT Analysis Product List.pdf
RobertPhillips265023
Human Resource Management Chapter 9: Performance Management and Appraisal
Human Resource Management Chapter 9: Performance Management and Appraisal
gomezdominic3
Último
(20)
Ethical stalking by Mark Williams. UpliftLive 2024
Ethical stalking by Mark Williams. UpliftLive 2024
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
Intellectual Property Licensing Examples
Intellectual Property Licensing Examples
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023
Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024
Al Taj Al Malaki Company Profile -------
Al Taj Al Malaki Company Profile -------
AL Satwa Dubai Call Girls +971552825767 Call Girls In AL Karama
AL Satwa Dubai Call Girls +971552825767 Call Girls In AL Karama
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
The End of Business as Usual: Rewire the Way You Work to Succeed in the Consu...
The End of Business as Usual: Rewire the Way You Work to Succeed in the Consu...
Data skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story points
IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...
IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024
Q2 2024 APCO Geopolitical Radar - The Global Operating Environment for Business
Q2 2024 APCO Geopolitical Radar - The Global Operating Environment for Business
MoneyBridge Pitch Deck - Investor Presentation
MoneyBridge Pitch Deck - Investor Presentation
Company Profile and SWOT Analysis Product List.pdf
Company Profile and SWOT Analysis Product List.pdf
Human Resource Management Chapter 9: Performance Management and Appraisal
Human Resource Management Chapter 9: Performance Management and Appraisal
Working in a_regulated_environment_presentation_ngan-winward
1.
© 2013 Vivid
Ngenuity, LLC. All rights reserved. 1 Bio-Link Summer Fellows Forum 2013 Vivian Ngan-Winward, PhD, CMQ/OE WORKING IN A REGULATED ENVIRONMENT – ARE YOUR BIOTECH STUDENTS PREPARED?
2.
THIS WORKSHOP COVERS
. . . Overview of a regulated environment Basics of FDA regulations How biotech companies comply Common FDA inspection observations How to prepare students for Working in a regulated environment Making contributions toward compliance 2 © 2013 Vivid Ngenuity, LLC. All rights reserved.
3.
3 BIOTECHNOLOGY INDUSTRY OVERVIEW © 2013 Vivid
Ngenuity, LLC. All rights reserved.
4.
4 BIOTECH PRODUCT LIFE
CYCLE Idea Research & Development [„Proof of Concept‟] Prototyping / Pilot Plant [Validation & Smaller Scale Production] Manufacturing [Mass / Large Scale Production] Consumer © 2013 Vivid Ngenuity, LLC. All rights reserved. Business strategy : Develop for manufacturability Initiate compliance efforts at the idea stage (identify market)
5.
MARKETING PRODUCTS Requires
FDA approval / clearance Pre-clinical & clinical trials Submit application Include data to support : o Product claims o Product safety Approval / clearance given by appropriate FDA center with oversight for product type 5 © 2013 Vivid Ngenuity, LLC. All rights reserved.
6.
6 WHY THE NEED
FOR REGULATIONS ? © 2013 Vivid Ngenuity, LLC. All rights reserved.
7.
. . .
LESSONS FROM THE PAST 7 1800’s Poor meat-packing conditions → Upton Sinclair’s The Jungle Federal Food and Drug Act → first regulation of product labeling 1960 Federal Food, Drug, & Cosmetic (FD&C) Act USDA Bureau of Chemistry → Food, Drug, and Insecticide Administration (to FDA in 1930) Misbranding (e.g. labeling is false or misleading) : food, “tonics”, “elixirs of life” © 2013 Vivid Ngenuity, LLC. All rights reserved. 1906 1938 1927 Sulfanilamide elixir disaster : 107 deaths !!!1937 Application for Kevadon denied (Frances Kelsey); thalidomide disaster in Europe (1961-1962)
8.
. . .
LESSONS FROM THE PAST (CONT.) 8 FD&C Act Medical Device Amendments GXPs GMP for Blood & Blood components – 21 CFR 606 (1975) GMP for Drugs - 21 CFR 210 & 211 (1978) GLP – 21 CFR 58 (1978) for pre-clinical studies GMP for Food – 21 CFR 110 (1986) GMP for Medical Devices [QSR] – 21 CFR 820 (1996) GMP for Dietary Supplements – 21 CFR 111 (2007) 1970’s - now © 2013 Vivid Ngenuity, LLC. All rights reserved. 1976 FD&C Act Kefauver-Harris Amendments1962 Dalkon Shield disaster1971
9.
A CLOSER LOOK
– FD&C ACT (1938) Extended control to cosmetics and therapeutic devices Required new drugs to be shown safe before marketing Eliminated Sherley Amendment requirement (to prove intent to defraud in drug misbranding cases) Provided for safe tolerances be set for unavoidable poisonous substances Authorized standards of identity, quality, and fill-of- container for foods Authorized factory inspections Added of court injunctions to the penalties 9 © 2013 Vivid Ngenuity, LLC. All rights reserved.
10.
A CLOSER LOOK
– KEFAUVER-HARRIS AMD. (1962) Required manufacturers to provide evidence that proposed drugs were both safe and effective, demonstrated by adequate and well-controlled clinical investigations conducted by qualified experts Required FDA evaluation of new drug applications (180 days); applications would no longer become automatically effective Required affirmative FDA decision of new drugs before marketing Required manufacturers to maintain records of adverse drug events and to report these promptly to FDA 10 © 2013 Vivid Ngenuity, LLC. All rights reserved.
11.
BENEFITS OF REGULATIONS
Sets standards for manufacturers and expectations for their products Protects the public: some assurance of safety and efficacy 11 © 2013 Vivid Ngenuity, LLC. All rights reserved.
12.
REGULATIONS REFERENCES 12 FDA
: What We Do : History http://www.fda.gov/AboutFDA/WhatWe Do/History/default.htm Sinclair (1906) The Jungle © 2013 Vivid Ngenuity, LLC. All rights reserved.
13.
STUDENT PREPARATION IDEAS 13
Discussion on an aspect of regulations history Research / presentation on one of the product “disasters” Goal: orientation to the history and importance of regulations © 2013 Vivid Ngenuity, LLC. All rights reserved.
14.
14 THE LAWS & CODE
OF FEDERAL REGULATIONS © 2013 Vivid Ngenuity, LLC. All rights reserved.
15.
LAWS → REGULATIONS 15 FDA United
States Code (U.S.C.) – Title 21 US Federal Government Code of Federal Regulations (CFRs) – Title 21, Food & Drugs Promulgated in Federal Register Laws Codified © 2013 Vivid Ngenuity, LLC. All rights reserved.
16.
FD&C ACT OVERVIEW
Chapter I: Short Title Chapter II: Definitions Chapter III: Prohibited Acts and Penalties Chapter IV: Food Chapter V: Drugs and Devices Chapter VI: Cosmetics Chapter VII: General Authority Chapter VIII: Imports and Exports Chapter IX: Miscellaneous 16 © 2013 Vivid Ngenuity, LLC. All rights reserved.
17.
FD&C ACT OVERVIEW
(CONT.) 17 © 2013 Vivid Ngenuity, LLC. All rights reserved. FD&C Act / U.S.C. section number cross- reference http://www.fda.gov/RegulatoryInformation /Legislation/FederalFoodDrugandCosmeti cActFDCAct/default.htm
18.
21 CFR OVERVIEW Parts
Covers 100 series Food – 110 cGMPs ; Dietary supplements – 111 cGMPs 200 & 300 series Pharmaceuticals – 210 & 211 cGMPs 500 series Animal feeds & medications 600 series Biological products – 606 cGMPs 700 series Cosmetics (limited regulations) 800 series Medical devices – 820 cGMPs 900 series Mammography quality requirements 1000 series Radiation emitting device 1200 series Non-FD&C Act rulings Other GLP – 58; GCP – 50, 54, 56; Electronic Records – 11 18 © 2013 Vivid Ngenuity, LLC. All rights reserved.
19.
21 CFR ? 21
CFR Parts can be viewed at http://www.ecfr.gov 19 © 2013 Vivid Ngenuity, LLC. All rights reserved.
20.
STUDENT PREPARATION IDEAS 20
Select several 21 CFR Parts and assign one to each student to summarize and present to the class Assign students to select and report on one 21 CFR Part of interest Goal: exposure to 21 CFRs, and how to find them © 2013 Vivid Ngenuity, LLC. All rights reserved.
21.
21 FOOD AND DRUG ADMINISTRATION ©
2013 Vivid Ngenuity, LLC. All rights reserved.
22.
FDA OVERVIEW An
agency of Department of Health and Human Services (as of 1979) Mission: 1. “ responsible for protecting the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation ” 22 © 2013 Vivid Ngenuity, LLC. All rights reserved.
23.
FDA OVERVIEW (CONT.)
Mission (cont.): 2. “ responsible for advancing the public health by helping to speed innovations that make medicines and foods more effective, safer, and more affordable; and helping the public get the accurate, science-based information they need to use medicines and foods to improve their health ” 23 © 2013 Vivid Ngenuity, LLC. All rights reserved.
24.
FDA ORGANIZATION 24 From: www.fda.gov/AboutFDA/CentersOffices/OrganizationCharts/default.htm ©
2013 Vivid Ngenuity, LLC. All rights reserved.
25.
FDA ORGANIZATION (CONT.) 25 ©
2013 Vivid Ngenuity, LLC. All rights reserved. Subdivision Responsibility Office of the Commissioner Program administration Office of Regulatory Affairs Enforces FDA regulations, monitors industry for compliance, recalls Center for Biologics Evaluation & Research (CBER) Assorted biological products/biologics (these replicate natural human substances): allergenic extracts for shots, blood & blood components, gene therapy products, transplant-related human tissue and cellular products, vaccines FDA Subdivisions:
26.
FDA ORGANIZATION (CONT.
2) 26 © 2013 Vivid Ngenuity, LLC. All rights reserved. Subdivision Responsibility Center for Drug Evaluation & Research (CDER) Drugs (purely chemical substances), therapeutic biological products (e.g. monoclonal Abs, cytokines, growth factors, enzymes, thrombolytics, proteins [natural or recombinant]) extracted from animals for therapeutic use, non-vaccine therapeutic immunotherapies Center for Devices & Radiological Health (CDRH) Medical devices (e.g. catheters, breast pumps, contact lenses, lab instrumentation), diagnostic test kits, GMP, compliance, postmarket tracking, radiological health screening procedures (mammography, whole body CT scanning, medical imaging) FDA Subdivisions (continued):
27.
FDA ORGANIZATION (CONT.
3) 27 © 2013 Vivid Ngenuity, LLC. All rights reserved. Subdivision Responsibility Center for Food Safety & Applied Nutrition (CFSAN) Various food products, GMOs, cosmetics, dietary supplements, infant formula, foodborne illness, food labeling & nutrition Center for Veterinary Medicine (CVM) Food additives and drugs given to animals; animals from which human foods are derived FDA Subdivisions (continued):
28.
BIOTECH PRODUCT JURISDICTION 28 Product
Type FDA Center Vaccine and blood product type therapeutic proteins CBER Some therapeutic biological products (mAbs for in vivo use, therapeutic proteins, cytokines and growth factors used as immunomodulators or alterers of cell production) Transferred to CDER Combination products (e.g. drug/device, biologic/device, drug/biologic, drug/device/biologic) – combined, packaged together, packaged separately but to be used together CBER, CDER, or CDRH, depends on primary mode of action Genetic tests for disease diagnosis or disease prevention, treatment, or cure CDRH Biosimilars (generic biologic, not identical to original) CDER © 2013 Vivid Ngenuity, LLC. All rights reserved.
29.
REGULATED PRODUCT APPROVALS Application
Type Purpose Investigational New Drug (IND) To request exemption of approved marketing application for shipping new drug across state lines for clinical trials New Drug Application (NDA) To request approval to sell and market new drug in US; submitted with supporting documentation detailing drug ingredients; how drug is manufactured, processed, and packaged; results of animal studies and clinical studies; how the drug behaves in the body Abbreviated New Drug Application (ANDA) To request approval to sell and market generic drug in US; application need not include animal and clinical studies, but must show evidence that generic is bioequivalent to innovator drug 29 © 2013 Vivid Ngenuity, LLC. All rights reserved. Drugs
30.
REGULATED PRODUCT APPROVALS (CONT.) Application
Type Purpose Over-the-Counter Drug (OTC) Not an application; manufacturer can sell and market an OTC drug with FDA pre-approval if it conforms to the FDA-published OTC monograph; one monograph for each of 80 therapeutic classes of OTC drugs; monograph contains acceptable ingredients, doses, formulation, and labeling, and defines safety and effectiveness Biologic License Application (BLA) To request approval to sell and market biologic in US; like a NDA but for a biologic 30 © 2013 Vivid Ngenuity, LLC. All rights reserved. Drugs . . . 2
31.
REGULATED PRODUCT APPROVALS (CONT.
2) 31 © 2013 Vivid Ngenuity, LLC. All rights reserved. Medical Devices Application Type Purpose Investigational Device Exemption (IDE) To request exemption of approved marketing application for shipping investigational device across state lines for clinical trials; clinical trials typically required to support premarket approvals, but occasionally needed to support premarket notifications Premarket Notification (PMN) / 510(k) Clearance To request clearance to sell and market in US non- exempt Class I device or Class II device that is substantially equivalent to a legally marketed (predicate) device Premarket Approval (PMA) To request approval to sell and market non-pre- amendment Class III or non-510(k) device in US
32.
REGULATED PRODUCT APPROVALS (CONT.
3) 32 © 2013 Vivid Ngenuity, LLC. All rights reserved. Medical Devices . . . 2 Application Type Purpose Humanitarian Device Exemption (HDE) To request exemption of certain requirements to sell and market humanitarian use device (HUD) in US that is intended to benefit patients through treatment or diagnosis of disease or condition affecting < 4,000 individuals per year; like a PMA but exempt from proof of effectiveness requirement
33.
REGULATED PRODUCT APPROVALS (CONT.
4) 33 © 2013 Vivid Ngenuity, LLC. All rights reserved. Medical Device Notes Device classification: o Depends on intended use and indications for use o Over 1,700 distinct devices, grouped into 16 medical specialty panels [per 21 CFR 862-892], have been classified o 3 classes: Class I, Class II, and Class III, with regulatory control increasing from I to III – see: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ Overview/GeneralandSpecialControls/default.htm
34.
REGULATED PRODUCT APPROVALS (CONT.
5) 34 © 2013 Vivid Ngenuity, LLC. All rights reserved. Medical Device Notes (cont.) Device Class Definition Class I • Low risk • Most (~74%) are exempt; non-exempt require PMN / 510(k) • Exempt manufacturers must still register establishment and list generic category or classification name • Exempt devices not exempt from GMP requirements; however, some are GMP exempt but not from records and complaint files • Some exempt devices have limitations to exemption status • Subject to general controls
35.
REGULATED PRODUCT APPROVALS (CONT.
6) 35 © 2013 Vivid Ngenuity, LLC. All rights reserved. Medical Device Notes (cont. 2) Device Class Definition Class II • Moderate risk • Most are not exempt and usually require PMN / 510(k) • Some are exempt, but not from GMP requirements • Subject to general controls, and special controls to assure safety and effectiveness Class III • High risk - pose significant risk of illness or injury (devices usually support or sustain human life); OR not substantially equivalent to Class I or Class II predicate • Not exempt and require PMA unless a pre-amendment (pre May 28, 1976) device • Subject to general controls with PMA
36.
REGULATED PRODUCT APPROVALS (CONT.
7) 36 © 2013 Vivid Ngenuity, LLC. All rights reserved. Medical Device Notes (cont. 3) Substantial equivalence: if, in comparison to predicate . . . o Has same intended use AND technological characteristics o Has same intended use BUT different technological characteristics that are supported by data that (1) shows device is at least as safe and effective as predicate AND (2) does not raise new safety and effectiveness questions
37.
FDA WEB SITE
RESOURCES Center–specific information for industry AND consumers About FDA Regulatory info & guidance documents Science & research News Recalls & alerts Approvals & clearances 37 © 2013 Vivid Ngenuity, LLC. All rights reserved.
38.
STUDENT PREPARATION IDEAS 38
Invite a local biotech company representative to speak to your class about the process required to achieve a recent product approval / clearance Examine and discuss an application for a recently approved / cleared product Goal: exposure to FDA submissions © 2013 Vivid Ngenuity, LLC. All rights reserved.
39.
39 GOOD ? PRACTICES (GXPS) ©
2013 Vivid Ngenuity, LLC. All rights reserved.
40.
WHAT ARE GXPS
? GXPs = “best” practices & FDA mandated defines what compliance requires does not describe exactly how to do it 40 © 2013 Vivid Ngenuity, LLC. All rights reserved.
41.
21 CFR OVERVIEW Parts
Covers 100 series Food – 110 cGMPs ; Dietary supplements – 111 cGMPs 200 & 300 series Pharmaceuticals – 210 & 211 cGMPs 500 series Animal feeds & medications 600 series Biological products – 606 cGMPs 700 series Cosmetics (limited regulations) 800 series Medical devices – 820 cGMPs 900 series Mammography quality requirements 1000 series Radiation emitting device 1200 series Non-FD&C Act rulings Other GLP – 58; GCP – 50, 54, 56; Electronic Records – 11 41 © 2013 Vivid Ngenuity, LLC. All rights reserved.
42.
DIFFERENT GXPS Good
clinical practices (GCP) : Regulates clinical trials involving human subjects Protects human rights Provides assurance of safety and efficacy of developed product Good laboratory practices (GLP) : Regulates nonclinical laboratory studies that support FDA approval applications Good manufacturing practices (cGMP) : Regulates manufacture of products covered by FD&C Act 42 © 2013 Vivid Ngenuity, LLC. All rights reserved.
43.
GOOD MANUFACTURING PRACTICES (GMP)
Most stringently described in 21 CFR Parts 110 : for food 111 : for dietary supplements 210 & 211 : for drugs 606 : for biologics 820 : for medical devices (QSRs) Provides detailed requirements on how to operate manufacturing business Indirectly impacts R&D 43 © 2013 Vivid Ngenuity, LLC. All rights reserved.
44.
GMP DESIGN CONTROLS
Design Inputs & Outputs Design Verification : Outputs = Inputs Design Validation Compilation of records: Design History File (DHF) : describes design history of finished product Device Master Record (DMR) : contains procedures and specifications of finished device/product (“recipe”) Device History Record (DHR) : contains production history of device/product 44 © 2013 Vivid Ngenuity, LLC. All rights reserved.
45.
GMP EXAMPLE Medical
device cGMP up close . . . See also : FDA’s CDRH Learn – Quality System Regulation 21 CFR 820 Basic Introduction presentation http://www.fda.gov/MedicalDevices/ResourcesforYou /Industry/ucm126252.htm 45 © 2013 Vivid Ngenuity, LLC. All rights reserved.
46.
GXP REFERENCES GLP: o
21 CFR 58 o Lab Compliance GLP tutorial http://www.labcompliance.com/tutorial/gl p/default.aspx?sm=d_a o WHO GLP Handbook (2009) http://www.who.int/tdr/publications/traini ng-guideline-publications/good-laboratory- practice-handbook-ver1/en/ 46 © 2013 Vivid Ngenuity, LLC. All rights reserved.
47.
GXP REFERENCES (CONT.)
GMP FDA guidance documents: o http://www.fda.gov/Drugs/GuidanceComplian ceRegulatoryInformation/Guidances/ucm06497 1.htm o http://www.fda.gov/BiologicsBloodVaccines/G uidanceComplianceRegulatoryInformation/Gui dances/General/ucm217665.htm o http://www.fda.gov/MedicalDevices/DeviceRe gulationandGuidance/PostmarketRequirements /QualitySystemsRegulations/MedicalDeviceQua litySystemsManual/default.htm 47 © 2013 Vivid Ngenuity, LLC. All rights reserved.
48.
STUDENT PREPARATION IDEAS 48
GXP comparison activity: Align these 21 CFR Parts: o GLP (21 CFR 58) o drug cGMP (21 CFR 210 & 211) o biologics cGMP (21 CFR 606) o medical device cGMP (21 CFR 820) Goal: exposure to details of GXPs and how they are similar / different © 2013 Vivid Ngenuity, LLC. All rights reserved.
49.
49 REGULATORY COMPLIANCE © 2013 Vivid
Ngenuity, LLC. All rights reserved.
50.
THE HIERARCHY A tight
relationship exists between the FDA [regulating body] the Laws [US Code] the Code of Federal Regulations (CFRs) - gov’t agency promulgated Good Manufacturing Practices (GMPs) Quality System Regulations (QSRs) Standards / Certifications (e.g. ISO) Quality Management System 50 FDA Laws (U.S.C.) Industry-Specific CFRs GMPs Quality Management System GovernmentIndustryCompany Standards / Certif. (e.g. ISO) QSRs ISO Non-gov‟tOrg © 2013 Vivid Ngenuity, LLC. All rights reserved.
51.
COMPLYING WITH FDA
REGS How ? 51 © 2013 Vivid Ngenuity, LLC. All rights reserved.
52.
“INTERPRETING REGULATIONS” 52 © 2013
Vivid Ngenuity, LLC. All rights reserved. What does the sign mean to you ? How will you ensure compliance ?
53.
COMPLYING WITH FDA
REGS . . . 2 By appropriately interpreting the regulations 53 © 2013 Vivid Ngenuity, LLC. All rights reserved.
54.
COMPLYING WITH FDA
REGS . . . 3 A quality management system provides a structure for the company to work within and remain compliant 54 © 2013 Vivid Ngenuity, LLC. All rights reserved.
55.
55 QUALITY MANAGEMENT SYSTEM © 2013 Vivid
Ngenuity, LLC. All rights reserved.
56.
QUALITY MANAGEMENT SYSTEM (QMS)
– CHARACTERISTICS Required by the FDA (not optional !) “Each manufacturer shall establish and maintain a quality system that is appropriate for the specific medical device(s) designed or manufactured, and that meets the requirements of this part.” – 21 CFR 820.5 Designed by each company to align its operations with the regulations 56 © 2013 Vivid Ngenuity, LLC. All rights reserved.
57.
WHAT IS A
QMS ? Per 21 CFR 820.3 – “the organizational structure, responsibilities, procedures, processes, and resources for implementing quality management” Per Wikipedia – “a set of policies, processes, and procedures required for planning and execution of production in the core business area of an organization” 57 © 2013 Vivid Ngenuity, LLC. All rights reserved.
58.
WHAT IS A
QMS ? (CONT.) Has a customer focus Often designed to meet ISO 9001 standards – based on 8 principles: 1. Customer focus 2. Leadership 3. Workforce involvement 4. Continuous improvement 5. System approach to management 6. Data-based approach to decision making 7. Positive supplier communication / relationships 8. Total process approach 58 © 2013 Vivid Ngenuity, LLC. All rights reserved.
59.
WHAT IS A
QMS ? (CONT. 2) Main components Management responsibility Resource management Product realization Measurement, analysis, and improvement Process-oriented approach to managing quality A framework that directs quality contributions from all employees 59 © 2013 Vivid Ngenuity, LLC. All rights reserved.
60.
QMS PROCESS MODEL 60 Quality
Management System Continual Improvement Resource Management Process / Product Realization input Product / Service C U S T O M E R R e q u i r e m e n t s Measurement, Analysis, & Improvement Management Responsibility output S a t i s f a c t i o n © 2013 Vivid Ngenuity, LLC. All rights reserved. C U S T O M E R
61.
WHAT DOES THE
QMS COVER ? Training & qualifying personnel Controlling product design Controlling documentation & records Controlling purchasing Identifying & tracing product at all production stages Defining & controlling production & processes Defining & controlling inspection / measuring / test equipment 61 © 2013 Vivid Ngenuity, LLC. All rights reserved.
62.
WHAT DOES THE
QMS COVER ? (CONT.) Validating processes Accepting product Controlling nonconforming product Instituting corrective & preventive actions Controlling labeling & packaging Servicing production equipment Using statistical techniques 62 © 2013 Vivid Ngenuity, LLC. All rights reserved.
63.
COMMON FDA OBSERVATIONS
Catalogued by the FDA on an annual basis Access through: http://www.fda.gov/ICECI/EnforcementAc tions/ucm250720.htm Examples from FDA inspections during fiscal year 2012 (Oct 1, 2011 to Sep 30, 2012) – actual observations reported on Form 483’s 63 © 2013 Vivid Ngenuity, LLC. All rights reserved.
64.
DRUG OBSERVATIONS .
. . 1 © 2013 Vivid Ngenuity, LLC. All rights reserved. Observation Freq Reg Ref The responsibilities and procedures applicable to the quality control unit are not [in writing] [fully followed]. Specifically, *** 169 21 CFR 211.22(d) There is a failure to thoroughly review [any unexplained discrepancy] [the failure of a batch or any of its components to meet any of its specifications] whether or not the batch has been already distributed. Specifically, *** 119 21 CFR 211.192 There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess. Specifically, *** 116 21 CFR 211.100(a)
65.
DRUG OBSERVATIONS .
. . 2 © 2013 Vivid Ngenuity, LLC. All rights reserved. Observation Freq Reg Ref Laboratory controls do not include the establishment of scientifically sound and appropriate [specifications] [standards] [sampling plans] [test procedures] designed to assure that [components] [drug product containers] [closures] [in-process materials] [labeling] [drug products] conform to appropriate standards of identity, strength, quality and purity. Specifically, *** 115 21 CFR 211.160(b) Control procedures are not established which [monitor the output] [validate the performance] of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product. Specifically, *** 89 21 CFR 211.110(a)
66.
DRUG OBSERVATIONS .
. . 3 © 2013 Vivid Ngenuity, LLC. All rights reserved. Observation Freq Reg Ref Written procedures are not [established] [followed] for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product. Specifically, *** 73 21 CFR 211.67(b) Routine [calibration] [inspection] [checking] of [automatic] [mechanical] [electronic] equipment is not performed according to a written program designed to assure proper performance. Specifically, *** 69 21 CFR 211.68(a) Employees are not given training in [the particular operations they perform as part of their function] [current good manufacturing practices] [written procedures required by current good manufacturing practice regulations]. Specifically, *** 65 21 CFR 211.25(a)
67.
DRUG OBSERVATIONS .
. . 4 © 2013 Vivid Ngenuity, LLC. All rights reserved. Observation Freq Reg Ref Equipment and utensils are not [cleaned] [maintained] [sanitized] at appropriate intervals to prevent [malfunctions] [contamination] that would alter the safety, identity, strength, quality or purity of the drug product. Specifically, *** 65 21 CFR 211.67(a) Written production and process control procedures are not [followed in the execution of production and process control functions] [documented at the time of performance]. Specifically, *** 64 21 CFR 211.100(b)
68.
DRUG OBSERVATIONS .
. . 5 © 2013 Vivid Ngenuity, LLC. All rights reserved. Observation Freq Reg Ref Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the [final specifications] [identity and strength of each active ingredient] prior to release. Specifically, *** 62 21 CFR 211.165(a)
69.
DEVICE OBSERVATIONS .
. . 1 © 2013 Vivid Ngenuity, LLC. All rights reserved. Observation Freq Reg Ref Procedures for corrective and preventive action have not been [adequately] established. Specifically, *** 372 21 CFR 820.100(a) Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been [adequately] established. Specifically,*** 259 21 CFR 820.198(a) Written MDR procedures have not been [developed] [maintained] [implemented]. Specifically, *** 140 21 CFR 803.17 Procedures to ensure that all purchased or otherwise received product and services conform to specified requirements have not been [adequately] established. Specifically, *** 126 21 CFR 820.50
70.
DEVICE OBSERVATIONS .
. . 2 © 2013 Vivid Ngenuity, LLC. All rights reserved. Observation Freq Reg Ref Corrective and preventive action activities and/or results have not been [adequately] documented. Specifically, *** 115 21 CFR 820.100(b) Procedures have not been [adequately] established to control product that does not conform to specified requirements. Specifically, *** 110 21 CFR 820.90(a) A process whose results cannot be fully verified by subsequent inspection and test has not been [adequately] validated according to established procedures. Specifically, *** 102 21 CFR 820.75(a) Procedures for design change have not been [adequately] established. Specifically,*** 101 21 CFR 820.30(i)
71.
DEVICE OBSERVATIONS .
. . 3 © 2013 Vivid Ngenuity, LLC. All rights reserved. Observation Freq Reg Ref Complaints involving the possible failure of [a device] [labeling] [packaging] to meet any of its specifications were not [reviewed] [evaluated] [investigated] where necessary. Specifically, *** 96 21 CFR 820.198(c) Procedures for quality audits have not been [adequately] established. Specifically, *** 91 21 CFR 820.22 A device master record has not been [adequately] maintained. Specifically, *** 91 21 CFR 820.181
72.
COMMONALITY Procedures for
XXX not [adequately] established / followed © 2013 Vivid Ngenuity, LLC. All rights reserved.
73.
STUDENT PREPARATION IDEAS 73
Review and discuss these common observations with students Case studies – select Form 483’s for class review and discussion (RE: local companies have more relevance) http://www.fda.gov/AboutFDA/CentersOffices/Offi ceofGlobalRegulatoryOperationsandPolicy/ORA/ORA ElectronicReadingRoom/default.htm Goal: understand common mistakes to better contribute toward compliance © 2013 Vivid Ngenuity, LLC. All rights reserved.
74.
QUESTIONS ? 74 Vivian Ngan-Winward vivian.ngan-winward@slcc.edu 801-957-6210 ©
2013 Vivid Ngenuity, LLC. All rights reserved.